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Our aim was to compare the effects of calcium carbonate and sevelamer-HCl treatments on calcium-phosphate metabolism and
renal function in 5/6 nephrectomized (NX) rats so that long-term disease progression preceded the treatment. After 15-week
progression, calcium carbonate (3.0%), sevelamer-HCl (3.0%), or control diets (0.3% calcium) were given for 9 weeks. Subtotal
nephrectomy reduced creatinine clearance (−40%), plasma calcidiol (−25%), and calcitriol (−70%) and increased phosphate
(+37%), parathyroid hormone (PTH) (11-fold), and fibroblast growth factor-23 (FGF-23) (4-fold). In NX rats, calcium carbonate
diet increased plasma (+20%) and urinary calcium (6-fold), reduced plasma phosphate (−50%) and calcidiol (−30%), decreased
creatinine clearance (−35%) and FGF 23 (−85%), and suppressed PTH without influencing blood pH. In NX rats, sevelamer-HCl
increased urinary calcium (4-fold) and decreased creatinine clearance (−45%), PTH (−75%), blood pH (by 0.20 units), plasma
calcidiol (−40%), and calcitriol (−65%). Plasma phosphate and FGF-23 were unchanged. In conclusion, when initiated after
long-term progression of experimental renal insufficiency, calcium carbonate diet reduced plasma phosphate and FGF-23 while
sevelamer-HCl did not. The former induced hypercalcemia, the latter induced acidosis, while both treatments reduced vitamin D
metabolites and deteriorated renal function. Thus, delayed initiation influences the effects of these phosphate binders in remnant
kidney rats.
1. Introduction
Cardiovascular disease is a major cause of mortality in
chronic renal insufficiency (CRI) with a 20-fold increase
in the risk of cardiovascular death compared with normal
population [1]. Hyperphosphatemia and secondary hyper-
parathyroidism (SHPT) [2] significantly contribute to the
cardiovascular pathology andmineral-bone disorders inCRI.
In order to halt these changes, oral phosphate binders such as
calcium carbonate and sevelamer are widely used.
High intake of calcium carbonate may predispose to
vascular calcifications in CRI, especially if the phosphate
levels remain inappropriately high [2]. Consequently, treat-
ment with sevelamer, a calcium- and aluminium-free and
nonabsorbable polyallylamine anion exchange resin, may
result in less vascular calcifications and reduced mortality
in dialysis patients. However, according to recent Cochrane
review, the superiority of sevelamer over calcium carbonate
remains unclear [3].
In experimental animal models, increased calcium intake
has resulted in beneficial effects on blood pressure (BP),
endothelial function, sodium-potassium balance, inflamma-
tion and thrombosis, plasma cholesterol levels, and insulin
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Figure 1: The flow chart of the study. Surgery (5/6 nephrectomy, NX; Sham-operation, Sham) was performed at entry, followed by 15-week
disease progression period. The animals were then allocated to control (0.3% calcium; Sham, NX), 3% calcium carbonate (Ca-Sham and Ca-
NX), or 3% sevelamer-HCl diet (Seve-Sham and Seve-NX) for 9 weeks. The values in parentheses indicate the number of animals/group at
each phase of the experiment.
sensitivity [4]. We have recently reported in three separate
studies that phosphate binding using calcium carbonate sup-
pressed angiotensin-converting enzyme (ACE) expression in
the kidney [5, 6], enhanced vasorelaxation of mesenteric
arteries via endogenous NO, and suppressed elevation of
aortic ACE and nitrated proteins in experimental CRI [7].
Sevelamer has a clinically proven positive impact on
SHPT, and it has also been reported to improve plasma
lipid profile and endothelial function in renal patients [3, 8].
However, when bound to hydrochloride, it has aggravated
metabolic acidosis in uremic patients due to increased acid
load [9], and it was subsequently replaced by sevelamer
carbonate [10, 11]. The previous studies using sevelamer-
HCl might have had both negative and positive bias due
to metabolic acidosis, which has been reported to decrease
serum calcitriol [12–14], negatively influence bone mineral
deposition [15], reduce cardiovascular calcifications [16], and
negatively influence overall survival [9]. Of note, information
on pH was not included in the majority of previous exper-
imental CRI studies using sevelamer-HCl [17–29]. There is
also evidence that sevelamer can impair the absorption of
vitamin D and other liposoluble molecules from the gut [30–
32].
In most of the experimental CRI studies, various treat-
ments have been started very shortly after the induction of
renal damage, but this is seldom possible in clinical practice.
In particular, complications like calcium carbonate-induced
hypercalcemia and sevelamer-HCl-induced acidosis might
constitute more severe problems in well-established CRI
after a prolonged period of compromised mineral and acid-
base balance. Our aim was to examine the influences of
long-term 3.0% calcium carbonate and 3.0% sevelamer-HCl
treatments on calcium-phosphate metabolism and kidney
function, and also on cardiac load and survival, in the surgical
5/6 nephrectomy rat model of CRI so that an extended 15-
week disease progression period preceded the treatments.
2. Methods
2.1.AnimalsandExperimentalDesign. Ninety-fivemale Spra-
gue-Dawley rats were subjected to surgical 5/6 nephrectomy
(NX, 𝑛 = 51) or Sham operation (𝑛 = 44) at 8 weeks of age
under ketamine/diazepam anesthesia (75 and 2.5mg/kg,
resp.). The NX surgery comprised removal of the upper
and lower poles of the left kidney followed by contralat-
eral nephrectomy. In the Sham group both kidneys were
decapsulated [5]. All rats were housed 3-4 per cage in
an animal laboratory with free access to water and chow
containing 0.9% calcium and 0.8% phosphate (LactaminR34,
AnalyCen, Lindko¨ping, Sweden). Average daily chow intake
was approximately 20 grams per rat, monitored in metabolic
cages.
After 15 weeks of disease progression, NX and Sham rats
were divided into three subgroups with equal systolic BPs,
body weights, and urine outputs (Figure 1). BP was measured
using tail-cuff (Model 129 BP Meter; IITC Inc., Woodland
Hills, CA, USA). NX groups were matched according to
plasma creatinine concentrations. Then for 9 weeks, Sham
(𝑛 = 14) andNX (𝑛 = 20) groups continued on 0.3% calcium,
Ca-Sham (𝑛 = 15) and Ca-NX (𝑛 = 16) rats on 3% calcium
carbonate, and Seve-Sham (𝑛 = 15) and Seve-NX (𝑛 = 15)
rats on 3% sevelamer-HCl. The doses of phosphate binders
(estimated at 1.3 g/kg) were chosen on the basis of previous
reports, none of which had reported major adverse effects
with 3.0% calcium carbonate or 3.0% sevelamer-HCl inges-
tion [17–29, 33, 34]. Sevelamer carbonate was not available at
the time this study was conducted. As 0.9% calcium content
in control chow is rather high, and lower dietary calcium
content has been used in several publications [19, 33, 34], the
calcium content in the present control chow was reduced to
0.3% similarly to our previous reports in experimental CRI
[5, 6].
During the final week, 24-hour water consumption was
measured and urine output was collected in metabolic
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cages. Then BPs were measured, and rats were weighed and
anesthetized (urethane 1.3 g/kg, intraperitoneally). Blood and
tissue samples were collected and stored at −70∘C. Due to
mortality, the final numbers for analyses in the uremic NX,
Ca-NX, and Seve-NX groups were 12, 11, and 10, respectively
(Figure 1). In each uremic group there was one rat that
survived through the 24-week experiment but expired before
BP measurements and sample collections and was only
included in the survival analyses.
The study design was approved by Tampere University
Animal ExperimentationCommittee and Provincial Govern-
ment of Western Finland, Department of Social Affairs and
Health, Finland. The investigation conforms to the Guide for
the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication Number 85-
23, revised 1996).
2.2. Hormonal and Chemical Analyses. Sodium, potassium,
creatinine, phosphate, and calcium concentrations weremea-
sured by standard clinical chemical methods (Cobas Integra
800 Clinical Chemical Analyzer, Roche Diagnostics, Basel,
Switzerland). Hemoglobin was determined photometrically
(Technicon H∗2, Technicon Instruments Corporation, Tar-
rytown, NY, USA), plasma pH was determined using an
ion selective electrode (634 pH Analyzer, Ciba Corning
Diagnostics, Sudbury, UK), and rat intact parathyroid hor-
mone (PTH) levels were determined by immunoradiometric
assay (Immutopics Inc., San Clemente, CA, USA). Plasma
1,25(OH)
2
D and 25(OH)D were determined using com-
mercial kits (IDS Ltd, Boldon, UK) and plasma fibroblast
growth factor-23 (FGF-23) was determined using ELISA kit
previously applied for analyses in rats (Kainos Inc., Tokyo,
Japan) [35]. Ventricular atrial natriuretic peptide (ANP)
mRNA was isolated and the radioimmunoassay was carried
out as described previously [36].
2.2.1. Calcification Analysis in the Aorta. Altogether 20 cross-
sections of the thoracic and 20 cross-sections of the abdom-
inal aorta from each animal were cut, and every 5th of
these sections were stained with the von Kossa method and
processed for light microscopy. An expert blinded to the
treatments quantified the calcifications.
2.2.2. Data Presentation and Analysis of Results. Statistical
analysis for normally distributed variables was carried out
using one-way analysis of variance (ANOVA) supported by
Tukey’s HSD test in the post hoc analyses (SPSS 17.0, SPSS
Inc., Chicago, IL, USA). If the distribution of a variable was
skewed, the Kruskal-Wallis test was applied and the post hoc
analyses were performed with the Mann-Whitney 𝑈 test.
Results were expressed asmean± SEM. Survival was analyzed
using theKaplan-Meier curves and the log-rank test.𝑃 < 0.05
denoted significance.
3. Results
3.1. Animal Data, Electrolytes, Renal Function, and Blood pH.
Figure 2 shows the survival rates in nephrectomized rats,
whichwere 65%, 75%, and 73% forNX,Ca-NX, and Seve-NX,
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Figure 2: Survival rates in Sham-operated and 5/6 nephrectomized
rats presented with Kaplan-Meier curves. Sham groups, all Sham-
operated groups; NX, 5/6 nephrectomized rats; Ca, 3% calcium
carbonate diet; Seve, 3% sevelamer-HCl diet; 𝑛 = 9–15; ∗
𝑃
< 0.05
versus Sham, #
𝑃
< 0.05 versus Ca-Sham, †
𝑃
< 0.05 versus NX, and
‡
𝑃
< 0.05 versus Ca-NX. 𝑃 values for NX groups and for NX versus
Sham groups are given.
respectively (𝑃 = 0.782). Table 1 shows the characteristics and
laboratory findings in the study groups.There were no signif-
icant differences in body weights between the groups during
the experiment (𝑃 > 0.114). The weights of the removed
kidney masses did not differ between the three NX groups
(𝑃 = 0.924). Before the treatments at week 15, no differences
were observed in BP (𝑃 = 0.739). At week 24, BPwas elevated
in all nephrectomized rats (𝑃 < 0.001), while Ca-NX rats
had lower BP than other uremic groups (𝑃 < 0.047). Heart
weight/bodyweight ratioswere increased in theNXand Seve-
NX groups (𝑃 ≤ 0.004) (Table 1). Increased left ventricular
ANP gene expression was detected in all NX groups (𝑃 <
0.001), showing the cardiac load in this model (Figure 3(a)).
Plasma creatinine was equally elevated in all NX groups
before the diets (𝑃 = 0.849) (Table 1). At week 24, creatinine
was 1.7-fold higher in the NX than the Sham group (𝑃 <
0.001). Most likely due to the loss of the animals with the
worst renal function, creatinine was not further elevated in
the NX group during the final 9-week follow-up. Both Seve-
NX (𝑃 < 0.009) and Ca-NX (𝑃 = 0.016) groups had higher
creatinine concentrations at week 24 than untreated NX rats
(Table 1). The 24-hour urine output was increased in all NX
groups (𝑃 ≤ 0.005) and was especially high in Seve-NX rats
(𝑃 < 0.001) (Figure 3(b)). Creatinine clearance was reduced
by ∼40% in untreated NX rats (𝑃 < 0.001) and was further
reduced in the CaNX (−35%, 𝑃 = 0.01) and Seve-NX groups
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Figure 3: Left ventricular ANP mRNA (a), urine volume (b), creatinine clearance (c), and 24-hour urinary calcium excretion at the close of
the study. Sham, sham-operated rats; NX, 5/6 nephrectomized rats; Ca, 3% calcium carbonate diet; Seve, 3% sevelamer-HCl diet; 𝑛 = 9–15;
∗
𝑃
< 0.05 versus Sham, #
𝑃
< 0.05 versus Ca-Sham, †
𝑃
< 0.05 versus NX, and ‡
𝑃
< 0.05 versus Ca-NX.
(−45%, 𝑃 = 0.01) when compared with untreated NX rats
(Figure 3(c)).
A blood pH reduction of approximately 0.2 units was
observed in both Sham and NX rats on sevelamer-HCL (𝑃 <
0.012) (Table 1). Plasma potassium was elevated in all NX
groups (𝑃 < 0.019), especially in Seve-NX rats (𝑃 < 0.001).
There were no significant differences in plasma sodium
concentrations between the groups (𝑃 = 0.108). Hemoglobin
was decreased in all NX groups (𝑃 ≤ 0.004) and was lowest
in Seve-NX rats (𝑃 < 0.001). Urinary protein excretion was
equally increased in all NX groups (𝑃 ≥ 0.920) and was ∼3.5-
fold higher in NX than in Sham rats (𝑃 ≤ 0.003) (Table 1).
3.2. Calcium-Phosphate Metabolism. Urinary calcium excre-
tion did not differ between the NX and the Sham groups
(𝑃 = 0.830) (Figure 3(d)) but was increased 10-fold in Ca-
Sham rats (𝑃 < 0.001) and 6-fold in Ca-NX rats (𝑃 < 0.001).
An in- crease in urinary calcium excretion was documented
in uremic rats which were on sevelamer-HCL (𝑃 = 0.008)
(Figure 3(d)). Plasma calciumwas highest in Ca-NX rats (𝑃 ≤
0.004) but was also increased in Ca-Sham (𝑃 < 0.001) and
Seve-NX rats (𝑃 = 0.023) (Figure 4(a)), so that calcium levels
did not differ in the two latter groups (𝑃 = 0.964). Plasma
phosphate was increased in NX (𝑃 = 0.01) and Seve-NX rats
(𝑃 = 0.001) and reduced in Ca-Sham (𝑃 < 0.001) and Ca-
NX rats (𝑃 = 0.002) (Figure 4(b)). Plasma Ca-Pi product
was elevated in the NX (𝑃 = 0.011) and Seve-NX groups
(𝑃 = 0.001) but was reduced in both calcium-supplemented
groups (𝑃 ≤ 0.047) (Table 1).
Plasma calcidiol was reduced by approximately 25% in
untreated NX rats (𝑃 = 0.019) and was further decreased
in the Ca-NX (𝑃 = 0.032) and Seve-NX groups (𝑃 =
0.002) (by ∼30% and ∼40% versus the untreated NX group,
resp.). Sevelamer-HCl reduced calcidiol concentration also in
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Figure 4: Plasma total calcium (a), phosphate (b), 25OH-D (c), 1,25(OH)
2
D (d), FGF-23 (e), and PTH (f) at the close of the study. Groups
as in Figure 3; ∗
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Sham-rats by 25% (𝑃 = 0.009) (Figure 4(c)). Calcitriol was
low in all uremic rats (𝑃 < 0.001), while both treatments (𝑃 ≤
0.001), especially sevelamer-HCl, decreased calcitriol even in
Sham rats (Figure 4(d)). FGF-23 levels were suppressed in
Ca-NX rats (𝑃 < 0.001), whereas in NX and Seve-NX rats
FGF-23 remained high (𝑃 ≤ 0.043) (Figure 4(e)). PTH was
increased 11-fold in the NX group (𝑃 = 0.001) and was totally
suppressed in both Ca-Sham and Ca-NX rats (𝑃 < 0.001).
PTH was also reduced by 75% in the Seve-NX group (𝑃 =
0.036), probably due to the elevated plasma calcium in these
animals (Figure 4(f)).
Even though altogether 8 aortic cross-sections were
analyzed from each rat, calcifications in the aortic samples
were scarce. In all uremic groups there were two rats with
calcifications in the thoracic aorta, while one rat in the Ca-
NX and one in the Seve-NX group also had calcifications in
the abdominal aorta.
4. Discussion
In the present study, we examined the effects of calcium
carbonate and sevelamer-HCl in established experimental
CRI with prolonged disease progression period preceding
the treatments. Unexpectedly, the undesirable side effects of
calcium carbonate and sevelamer-HCl overshadowed their
positive effects, and the treatments showed no survival
benefits. Calcium carbonate suppressed PTH and FGF-23 but
caused hypercalcemia especially in Ca-NX rats with impaired
renal excretion capacity. Sevelamer-HCl induced acidosis
in both Sham-operated and uremic rats, and consequently
no decreases in plasma phosphate or FGF-23 were seen.
Sevelamer-HCl also increased plasma calcium and urinary
calcium excretion and decreased PTH in NX rats. Both
treatments reduced vitamin D metabolites and impaired
kidney function. Neither calcium carbonate nor sevelamer-
HCl influenced aortic calcifications or mortality. The aortic
calcifications were scarce, as the NX model is quite resistant
to soft-tissue calcification in the absence of excess calcitriol
or phosphate loading [6, 37]. In previous studies, sevelamer-
HCl treatment did not induce renoprotective effects in
experimental CRI if irreversible kidney damage had already
taken place [21] but was clearly beneficial if initiated right
after the kidney insult [24].
The phosphate binding and FGF-23-reducing ability of
sevelamer-HCl [3, 20] seemed low in our study, although
estimated sevelamer-HCl intake was approximately
1300mg/kg/day in each rat (thus clearly exceeding the
maximum dose of about 140mg/kg/day in an average 70 kg
human). The acidosis of Seve-Sham and Seve-NX rats
indicates that they received hydrogen ions in excess in
the diet. Acidosis and consequent impairment of kidney
function with reduced phosphate excreting capacity were the
likely explanation for the high phosphate levels in Seve-NX
rats. Acidosis can deteriorate kidney function, whereas
bicarbonate treatment can delay the progression of CRI [38].
When the present results were adjusted for the differences
in creatinine, plasma phosphate was numerically lower
in the Seve-NX than NX group (1.61 versus 1.75mmol/L,
resp.). Creatinine clearance did not differ between Ca-NX
and Seve-NX rats, but the phosphate and the FGF-23 levels
were lower in Ca-NX rats, showing that calcium carbonate
functioned as a phosphate binder in this model.
A reason for the elevated phosphate in Seve-NX rats
may have been the calcium- and phosphate-releasing effect
of metabolic acidosis on bone [9, 15]. Increased urinary
calcium excretion in Seve-Sham and Seve-NX rats strongly
indicates increased calcium efflux from bone in the acidic
milieu [9]. As sevelamer-HCl is not absorbed and only binds
phosphate in the gut [9], it is not able to influence phosphate
levels resulting from increased internal release. The acidosis-
induced release of bone minerals was the likely cause for
increased plasma calcium and the subsequent significant
decrease in plasma PTH in Seve-NX rats, since extracellular
fluid calcium concentration is the primary regulator of PTH
release from the parathyroid glands [39]. In the Ca-NX rats,
significant dietary hypercalcemia was the most likely cause
for the deteriorated kidney function.
Although plasma calcitriol and calcidiol levels are typ-
ically reduced in CRI [40], we observed a further decline
of calcidiol in Ca-NX and Seve-NX rats, which may have
partially resulted from accelerated CRI in these animals.
The reasons for low plasma calcidiol in CRI are multiple,
including urinary loss of vitamin D binding protein and
vitamin D metabolites, reduced gastrointestinal absorption,
and decreased 25-hydroxylation in the liver [41]. Importantly,
decrease in calcidiol and calcitriol in the Seve-Sham group
corresponded to the reduction observed in untreatedNX rats.
Changes in calcium, phosphate, PTH, creatinine clearance
[14], FGF-23 [35], and urine protein excretion [42] would all
potentially influence plasma vitaminDmetabolite concentra-
tions. However, these variables did not differ between Sham
and Seve-Sham rats. Sevelamer-HCl also binds bile acids in
the gut [31] and interferes with the absorption of fat-soluble
vitamins D, E, and K [30, 32].This may explain the decreased
plasma calcidiol in Seve-Sham rats. In addition, reduced
calcitriol in Seve-Sham rats may also have resulted from
acidosis, which has been implicated in downregulation of
1alpha-hydroxylation and upregulation of 24-hydroxylation
[14]. In calcium carbonate-treated rats, potential mechanisms
for the reduced vitamin D metabolites were hypercalcemia
and subsequent suppression of PTH and impaired kidney
function of the Ca-NX group.
The present model of CRI was associated with increased
heart weight and left ventricular ANP mRNA expression.
Such changes can be explained by higher BP, volume load,
anemia, increased FGF-23, and vitamin D deficiency in the
NX groups [43–45]. Highest heart weights were observed
in Seve-NX rats, probably due to accelerated CRI, increased
volume load, and aggravated anemia [43]. Furthermore,
lowest calcitriol was seen in the Seve-NX rats and their FGF-
23 was equally high as in the untreated NX rats. Both of these
mechanisms have the potential to aggravate LVH [44, 45].
Acidosis may have influenced the results obtained in
previous sevelamer-HCl studies. Only two [33, 34] of the
fifteen experimental sevelamer-HCl studies reported blood
pH [17–29, 33, 34], and these studies applied the ligation
model of 5/6 nephrectomy with a disease progression period
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of only one week. Rats received 3.0% sevelamer-HCl or 3.0%
calcium carbonate for 12 weeks in the former study and for
24 weeks in the latter study. High mortality (about 80%)
in the latter study was observed in each uremic group. In
the surviving 20%, sevelamer-HCl had beneficial effects on
phosphate, PTH, and kidney function. Sevelamer-HCl also
increased calciuresis when compared with uremic controls
[33, 34]. Of note, the ligation 5/6 nephrectomy model results
in increased plasma renin activity [46, 47], while the surgical
model used here is characterized by low plasma renin and
reduced aldosterone [5, 48]. Low plasma aldosterone level
decreases hydrogen ion excretion in the kidneys [49], and
this probably exposed the present rats to acidosis. Reduced
pH in Seve-Sham rats indicates that excess hydrochloride
could cause acidosis even in healthy rats. In those previous
experimental studies with sevelamer-HCl that did not report
blood pH, increased plasma calcium concentration was
attributed to reduced phosphate levels [17–21, 29]. Some
studies also found increased calciuresis [17, 22, 25], which
was thought to result from reduced PTH [22, 25]. A dose-
dependent decrease in plasma calcitriol after sevelamer-HCl
treatment was observed in two previous studies [17, 25], one
of which also showed a clear reduction in plasma calcidiol
[17].
In conclusion, late-onset treatment with calcium carbon-
ate or sevelamer-HCl after 15 weeks of disease progression in
the 5/6 nephrectomy rat model of CRI showed no survival
benefits, and both treatments deteriorated kidney function
and reduced plasma calcidiol and calcitriol. In both Sham-
operated and remnant kidney rats, sevelamer-HCl treatment
induced acidosis, while calcium carbonate treatment induced
hypercalcemia. Finally, oral calcium carbonate, but not
sevelamer-HCl, effectively suppressed plasma phosphate and
FGF-23. Altogether, the present doses of phosphate binders,
albeit based on previous publications [5, 6, 48], seemed too
high for this model. The present findings also indicate that
the results from previous studies using sevelamer-HCl in
experimental CRI should be interpreted with caution due to
the possible bias resulting from acidosis-induced changes in
calcium-phosphate metabolism.
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